【摘要】 目的观察吉非替尼(gefitinib,ZD1839)治疗化疗失败的晚期非小细胞肺癌的疗效及毒副反应。方法2003年4月至2006年6月用吉非替尼治疗化疗失败的晚期非小细胞肺癌38例,服药至疾病进展或出现不可耐受的毒副反应。结果38例均可评价疗效,获得CR 0例,PR 8例(21.05%),SD 18例(47.37%),疾病控制率为68.42%,PD 12例(31.57%);中位生存时间7个月(1~26个月),中位疾病进展时间4.5个月,与药物相关的毒副反应为:皮疹19例(50%)、恶心10例(26.3%)、腹泻9例(23.68%)、皮肤干燥5例(13.16%)、乏力3例(7.89%),其它如发热、口腔溃疡及关节痛等毒副反应发生率均<5%,实验室指标末见明显异常。结论吉非替尼治疗化疗失败的晚期非小细胞肺癌疗效好,毒副反应少,耐受性好,可提高患者生活质量,延长生存期。更多还原

【Abstract】 Objective To observe the efficacy and drug-related toxicity of gefitinib(ZD1839) in the treatment of the 38 cases with advanced non-small cell lung cancer who failed to respond previous chemotherapy.Methods Thirty-eight non-small cell lung cancer patients who failed to respond previous chemotherapy were treated from Apr.2003 to Jun.2006.Gefitinib was given as a single drug at a dose of 250 mg per day orally until disease progressed or unacceptable toxicity occurred.Results Among these 38 patients,complete response 0(0%),partial response 8(21.05%), stable disease 18(47.37%),disease control rate 68.42%,progressive disease 12 (31.57%).Median survival time of the entire group was 7 months(1～26 months).Median time to progression was 4.5 months.The drug-related adverse reactions are skin rash 19(50%),nausea 10(26.3%),diarrhea 9(23.68%),xerosis cutis 5(13.16%),fatigue 3(7.89%).The rates of adverse reactions such as fever,dental ulcer and arthralgia were bellow 5%.The breadboard index is normal.Conclusions Gefitinib is an effective drug in the treatment of the cases with advanced nonsmall cell lung cancer who failed to respond previous chemotherapy.The toxicity can be well acceptable.更多还原